Silvercrest Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Silvercrest Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-180,502	Closed	-$3.64M	–	883
2021 Q3	$3.64M	Buy	180,502 +33,686	+23%	+$930K	0.02%	420
2021 Q2	$5.48M	Sell	146,816 -292	-0.2%	-$8.95K	0.04%	376
2021 Q1	$3.76M	Sell	147,108 -18,620	-11%	-$476K	0.03%	419
2020 Q4	$3.65M	Sell	165,728 -26,477	-14%	-$583K	0.03%	399
2020 Q3	$3.46M	Buy	192,205 +104,745	+120%	+$2.17M	0.03%	392
2020 Q2	$2.22M	Buy	+87,460	New	+$1.88M	0.02%	446

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Silvercrest Asset Management's DRNA Position: Q4 2021 in Review

Silvercrest Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 180,502 shares — an estimated $3.64M sold.

Silvercrest Asset Management first reported a position in DRNA in Q2 2020 and held it in 6 quarters. The position peaked at $5.48M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Silvercrest Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Silvercrest Asset Management sold 180,502 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $3.64M.
Silvercrest Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 6 quarters.
Silvercrest Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $5.48M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Silvercrest Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.